CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 33rd Annual J.P. Morgan Healthcare Conference being held in San Francisco. Marc Beer, chief executive officer of Aegerion, is scheduled to present on Monday, January 12, 2015 at 4:30 p.m. PST (7:30 p.m. EST).
The presentation and following Q&A session will be webcast live and may be accessed for up to 30 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.
Aegerion routinely posts information that may be important to investors in the "Investor Relations" section of the company's website at www.aegerion.com. Aegerion encourages investors and potential investors to consult this website regularly for important information about the company.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations & Public Relations 857-242-5024
Source:Aegerion Pharmaceuticals, Inc.